Australian (ASX) Stock Market Forum

AYA - Artrya Limited


27 June 2010
Reaction score
Artrya Limited (AYA) is a medical-technology company focused on commercialising its patented Salix suite of software products to improve detection and treatment of coronary artery disease (CAD). Salix uses artificial intelligence (AI) to automate the analysis and diagnosis of heart computed tomography (CT) scans, and help clinicians identify and manage patients at risk of a heart attack.

Artrya’s Salix Coronary Anatomy (SCA) Software as a Service (SaaS) product provides clinicians with rapid reporting of one of the strongest predictors of heart attack: Vulnerable Plaque. Named for its propensity to rupture and cause heart attack, Vulnerable Plaque is difficult and time-consuming to identify manually. As a result, Vulnerable Plaque, a leading cause of heart attack, is rarely reported.

Current practices to report CAD focus on the calcification and consequent narrowing of coronary arteries. Salix’s breakthrough technology analyses Coronary Computed Tomography Angiography (CCTA) scans to map Vulnerable Plaque and other coronary risk biomarkers. Salix generates a personalised 3D heart model and rapidly delivers an international-standard diagnostic report.

Already under development is Artrya’s next product, Salix Coronary Flow (SCF). Because SCF provides a non-invasive assessment of coronary blood flow, it could potentially reduce the number of unnecessary Invasive Coronary Angiogram (ICA) procedures.

It is anticipated that AYA will list on the ASX on 26 November 2021.


Dona Ferentes

11 January 2016
Reaction score
Listing date26 November 2021 12:30 PM AEDT##
Contact details
Ph: +61 8 6478 7816
Principal ActivitiesArtrya Limited is a medical technology company developing software which automates the analysis of heart computed tomography (CT) scans to assist in the diagnosis of Coronary Artery Disease.
GICS industry groupTBA
Issue PriceAUD 1.35
Issue TypeOrdinary Fully Paid Shares
Security codeAYA
Capital to be Raised$40,000,000
Expected offer close date29 October 2021
UnderwriterBell Potter Securities Limited (Underwriter/Lead Manager)